BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 26067224)

  • 1. Colorectal cancer screening in a low-incidence area: general invitation versus family risk targeting: a comparative study from Montenegro.
    Panic N; Rösch T; Smolovic B; Radunovic M; Bulajic M; Pavlovic-Markovic A; Krivokapic Z; Djuranovic S; Ille T; Bulajic M
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1222-5. PubMed ID: 26067224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
    Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
    Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.
    Van Roosbroeck S; Hoeck S; Van Hal G
    Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of colorectal cancer and adenomas in the families of patients with adenomas: a population-based study in Utah.
    Tuohy TM; Rowe KG; Mineau GP; Pimentel R; Burt RW; Samadder NJ
    Cancer; 2014 Jan; 120(1):35-42. PubMed ID: 24150925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk of colorectal neoplasia among family members of patients with colorectal cancer: a population-based study in Utah.
    Samadder NJ; Curtin K; Tuohy TM; Rowe KG; Mineau GP; Smith KR; Pimentel R; Wong J; Boucher K; Burt RW
    Gastroenterology; 2014 Oct; 147(4):814-821.e5; quiz e15-6. PubMed ID: 25042087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
    Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME
    Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk stratification and detection of new colorectal neoplasms after colorectal cancer screening with faecal occult blood test: experiences from a Danish screening cohort.
    Bjerrum A; Milter MC; Andersen O; Fischer A; Lynge E
    Eur J Gastroenterol Hepatol; 2015 Dec; 27(12):1433-7. PubMed ID: 26352132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal cancer risk factors in the detection of advanced adenoma and colorectal cancer.
    Stegeman I; de Wijkerslooth TR; Stoop EM; van Leerdam ME; Dekker E; van Ballegooijen M; Kuipers EJ; Fockens P; Kraaijenhagen RA; Bossuyt PM
    Cancer Epidemiol; 2013 Jun; 37(3):278-83. PubMed ID: 23491770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Screening for colorectal cancer in high-risk and intermediate-risk subject: what's the best tool?].
    Trevisani L; Cifalà V; Sartori S; Tombesi P; Matarese V; Pezzoli A; Abbasciano V
    Recenti Prog Med; 2009 Feb; 100(2):68-72. PubMed ID: 19350797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of stratifying by family history in colorectal cancer screening programs.
    Goede SL; Rabeneck L; Lansdorp-Vogelaar I; Zauber AG; Paszat LF; Hoch JS; Yong JH; van Hees F; Tinmouth J; van Ballegooijen M
    Int J Cancer; 2015 Sep; 137(5):1119-27. PubMed ID: 25663135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated screening with fecal immunochemical tests reduced the incidence of colorectal cancers in Saga, Japan.
    Sakata N; Sakata Y; Shimoda R; Sakata H; Iwakiri R; Fujimoto K; Mizuguchi M; Irie H; Shimoda Y; Noshiro H
    Hepatogastroenterology; 2014; 61(133):1224-8. PubMed ID: 25436287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial.
    Gupta S; Halm EA; Rockey DC; Hammons M; Koch M; Carter E; Valdez L; Tong L; Ahn C; Kashner M; Argenbright K; Tiro J; Geng Z; Pruitt S; Skinner CS
    JAMA Intern Med; 2013 Oct; 173(18):1725-32. PubMed ID: 23921906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
    Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
    Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
    Prince M; Lester L; Chiniwala R; Berger B
    World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of clinical risk stratification and fecal immunochemical test results to prioritize colonoscopy screening in asymptomatic participants.
    Aniwan S; Rerknimitr R; Kongkam P; Wisedopas N; Ponuthai Y; Chaithongrat S; Kullavanijaya P
    Gastrointest Endosc; 2015 Mar; 81(3):719-27. PubMed ID: 25708760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budget Impact Analysis of Against Colorectal Cancer In Our Neighborhoods (ACCION): A Successful Community-Based Colorectal Cancer Screening Program for a Medically Underserved Minority Population.
    Kim B; Lairson DR; Chung TH; Kim J; Shokar NK
    Value Health; 2017 Jun; 20(6):809-818. PubMed ID: 28577699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
    Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
    Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colonoscopic surveillance of first-degree relatives of colorectal cancer patients in a faecal occult blood screening programme.
    Sassoli de Bianchi P; Campari C; Mancini S; Giuliani O; Landi P; Paterlini L; Naldoni C; Finarelli AC; Falcini F; Ponz de Leon M; Sassatelli R; Borciani E; Fornari F; Gatti G; Zatelli M; Zurlini C; Rossi F; Corradini R; Olivetti R; Manfredi M; Baldazzi P; Nannini R; Zanarini S; Matarese VG; Palmonari C; Triossi O; Gordini S; Vattiato R; Colamartini A; Palazzi M; Severi M; Briganti L; Giovanardi M; Casale C; Bucchi L
    Cancer Epidemiol; 2013 Aug; 37(4):469-73. PubMed ID: 23683843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.